Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Centaur Pharma...

    Centaur Pharma Ambernath facility receives EIR from USFDA

    Farhat NasimWritten by Farhat Nasim Published On 2019-11-28T09:30:23+05:30  |  Updated On 16 Aug 2021 3:20 PM IST

    Centaur Pharma has now received a formal EIR (Establishment Inspection Report) from USFDA stating the facility is CGMP compliant and the audit outcome is categorized as VAI (Voluntary Action Indicated).


    Mumbai: Centaur Pharmaceuticals' state-of-the-art API Ambernath facility was audited by the USFDA and a 483 form was issued with one observation which was responded to, immediately.


    Centaur has now received a formal EIR (Establishment Inspection Report) from USFDA stating the facility is CGMP compliant and the audit outcome is categorized as VAI (Voluntary Action Indicated).


    This is the fifth successive GMP certification for the Centaur Ambernath API facility by the USFDA in a span of 11 years. In addition to the USFDA accreditation, the Ambernath facility conforms to EUGMP/ANSM (France), TGA, PMDA (Japan), KFDA (Korea), ANVISA (Brazil), COFEPRIS (Mexico) and WHO-GMP standards.


    Centaur is a manufacturer of psychotropic API. Centaur manufactures over 50 API, of which 32 have been introduced for the first time in India.


    Also Read: Biocon gets EIR from USFDA for Bengaluru biologics unit


    "Centaur Pharma has been diligently complying with GMP regulations to work towards zero observations in USFDA inspections. We have faced over fifteen audits by the USFDA in the past decade, for our various facilities and successfully cleared the same," said S.D. Sawant, Managing Director, Centaur Pharmaceuticals.


    "This is a proud moment for Centaur, and a significant milestone for the Indian pharmaceutical industry," he added.


    Earlier in May 2019, Centaur Pharmaceuticals' oral solid dosage facility in Pune had received no action indicated (NAI) compliance status, with zero 483 observations from the USFDA.


    In addition to the USFDA accreditation, the Pune facility also conforms to MHRA (UK), TGA (Australia), Health Canada, MCC (South Africa) and WHO-GMP standards.


    In September 2019 Life San, the clinical research division of Centaur Pharmaceuticals was audited by the US FDA and was concluded with zero 483 observations.


    Centaur Pharmaceuticals is a 100 million dollars Indian pharmaceutical company with exports to 110 countries. Centaur has a presence across the pharmaceutical value chain with proficiency in API, formulations, clinical research, and contract manufacturing.


    Centaur is ranked 35th in India by prescriptions and markets Sinarest the leader in the anticold prescription market for over two decades.


    Also Read: Cadila Healthcare gets EIR from USFDA for Baddi facility

    centaur Ambernath facilityCentaur pharmacGMPEIREstablishment Inspection Reportpsychotropicpsychotropic drugUSFDAUSFDA form 483USFDA inspectionVAIVoluntary Action Indicated
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok